Education
About Us
Working with TipRanks
Follow Us
Biogen (BIIB)
NASDAQ:BIIB
BIIB Stock Chart & Stats
$181.94
-$1.36(-0.89%)
At close: 4:00 PM EST
$181.94
-$1.36(-0.89%)
Day’s Range― - ―
52-Week Range$110.04 - $185.17
Previous CloseN/A
Volume268.56K
Average Volume (3M)1.86M
Market Cap
$26.69B
Enterprise Value$23.24B
Total Cash (Recent Filing)$3.96B
Total Debt (Recent Filing)$6.59B
Price to Earnings (P/E)16.6
Beta0.62
Next Earnings
Jan 29, 2026EPS Estimate
1.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.81
Shares Outstanding146,702,270
10 Day Avg. Volume2,339,367
30 Day Avg. Volume1,856,176
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)1.33
Price to Sales (P/S)2.30
P/FCF Ratio8.86
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue2.33
Enterprise Value/Gross Profit3.32
Enterprise Value/Ebitda6.65
Forecast
1Y Price Target
$184.00Price Target Upside1.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
EPS Forecast (FY)14.98
Revenue Forecast (FY)$9.81B
Bulls Say, Bears Say
Bulls Say
Earnings PerformanceQ3 results were strong with a significant beat driven by continued resilience in the MS segment.
Pipeline DevelopmentsBiogen is entering a catalyst-dense period with multiple late-stage opportunities across Alzheimer’s, lupus, SMA, and Parkinson’s.
Product Approval And LaunchesBiogen's diversification strategy is reinforced by the continued strong performance of Skyclarys and Zurzuvae.
Bears Say
Competitive EnvironmentThe broader competitive environment looks increasingly challenging with LL Y's Kisunla catching up to Leqembi's lead.
Growth OutlookThe growth outlook over the next few years remains lackluster, with revenues and EPS being flattish.
Sales PerformanceLeqembi sales of $121M underwhelmed, coming in 6% below consensus.
Biogen News
BIIB FAQ
What was Biogen’s price range in the past 12 months?
Biogen lowest stock price was $110.03 and its highest was $185.17 in the past 12 months.
What is Biogen’s market cap?
Biogen’s market cap is $26.69B.
When is Biogen’s upcoming earnings report date?
Biogen’s upcoming earnings report date is Jan 29, 2026 which is in 62 days.
How were Biogen’s earnings last quarter?
Biogen released its earnings results on Oct 30, 2025. The company reported $4.81 earnings per share for the quarter, beating the consensus estimate of $3.882 by $0.928.
Is Biogen overvalued?
According to Wall Street analysts Biogen’s price is currently Undervalued.
Does Biogen pay dividends?
Biogen does not currently pay dividends.
What is Biogen’s EPS estimate?
Biogen’s EPS estimate is 1.76.
How many shares outstanding does Biogen have?
Biogen has 146,702,270 shares outstanding.
What happened to Biogen’s price movement after its last earnings report?
Biogen reported an EPS of $4.81 in its last earnings report, beating expectations of $3.882. Following the earnings report the stock price went up 1.184%.
Which hedge fund is a major shareholder of Biogen?
Currently, no hedge funds are holding shares in BIIB
Biogen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$184.00 (1.13% Upside)
$184.00 (1.13% Upside)
Blogger Sentiment
Bullish
BIIB Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 725.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $69.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.37%
12-Months-Change
Fundamentals
Return on Equity
9.31%
Trailing 12-Months
Asset Growth
3.16%
Trailing 12-Months
Company Description
Biogen
Biogen Inc. is a global biotechnology company specializing in the discovery, development, and delivery of innovative therapies for neurological diseases. Founded in 1978 and headquartered in Cambridge, Massachusetts, Biogen focuses on areas such as multiple sclerosis, spinal muscular atrophy, and neurodegenerative diseases like Alzheimer’s. The company is recognized for its pioneering research in the field of neuroscience and offers several key products, including treatments like Tecfidera, Avonex, and Spinraza.
BIIB Company Deck
BIIB Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Biogen's earnings call reflected a strong performance in new product launches and pipeline progress, with significant revenue growth in key segments offsetting some challenges, particularly in Europe and China. The financial results and strategic focus on pipeline expansion suggest a positive outlook.View all BIIB earnings summariesBIIB Revenue Breakdown
74.55% Product revenue
18.09% Revenue from anti-CD20 therapeutic programs
6.74% Contract manufacturing, royalty and other revenue
0.62% Alzheimer's collaboration revenue
BIIB Stock 12 Month Forecast
Average Price Target
$184.00
▲(1.13% Upside)
Technical Analysis
Ownership Overview
0.17% Insiders
31.70% Mutual Funds
16.79% Other Institutional Investors
19.38% Public Companies and Individual Investors